Althea Technologies, a contract manufacturing organisation providing development and manufacturing services for biotechnology and pharmaceutical companies, has appointed Martha Demski as senior vice president (SVP) and chief financial officer (CFO). Demski will oversee the departments of finance, information technology, purchasing and corporate development, and will be responsible for developing strategies to support the company’s continued growth.
Demski brings over 30 years of experience in both privately held and publicly traded biotechnology companies and in the financial services industry. Most recently, she served as the interim chief operating officer (COO) and CFO of the Sidney Kimmel Cancer Centre. She previously served for over 15 years as vice president and CFO of Vical Incorporated, where she was responsible for multiple private and public financings, including an initial public offering (IPO).
In addition to Vical, Demski has held various positions with Bank of America, most recently as senior vice president (SVP) in their US trust division. Her board activities include the Board of Chimerix, where she currently serves as chair of the audit committee. She holds an MBA with concentrations in finance and accounting from The University of Chicago Booth School of Business, and a BA from Michigan State University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.